2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176783
    GNE-5152 3080315-83-6 98%
    GNE-5152 is an orthosteric SARM1 base-exchange (BE) inhibitor. GNE-5152 sustainably activates SARM1 at subinhibitory concentrations under mildly activating conditions, and this synergistic adverse effect increases NAD consumption, induces axon degradation and neurodegeneration and releases neurofilament-light (NfL) in cortical neurons. GNE-5152 can be used for neurodegenerative diseases research.
    GNE-5152
  • HY-176784
    Human MOG-specifying DNA 163913-87-9 98%
    Human MOG-specifying DNA is located at chromosome 6 within the human leukocyte antigen (HLA) gene locus. Human MOG-specifying DNA is exclusively expressed in the central nervous system (CNS) on the surface of myelin sheaths and oligodendrocytes (ODCs) processes, with unique methylation patterns in ODCs. Human MOG-specifying DNA can be used for inflammatory demyelinating diseases such as multiple sclerosis (MS) research.
    Human MOG-specifying DNA
  • HY-176800
    LMD-902 521979-59-9
    LMD-902, a LMD-009 (HY-121885) analog, is a CCR8 agonist with an EC50 of 15  nM. LMD-902 has a superior binging capacity depending on key residues such as PheVI:16. LMD-902 can be used for inflammation diseases like bronchial asthma and central nervous system diseases like multiple sclerosis research.
    LMD-902
  • HY-176827
    SOD1-IN-1 2640565-68-8 98%
    SOD1-IN-1 (comppund 9) is a potent SOD1 inhibitor. SOD1-IN-1 shows no cytotoxicity.
    SOD1-IN-1
  • HY-176856
    Maxi-K modulator 1 2748705-69-1
    Maxi-K modulator 1 (Example 1) is a Maximum conductance calcium-activated potassium (Maxi-K) channel modulator. Maxi-K modulator 1 has a potent stimulating effect on Maxi-K channel activity. Maxi-K modulator 1 can be used for fragile X syndrome research.
    Maxi-K modulator 1
  • HY-176863
    Di(5-(methylsulfonyl)-1,3,4-oxadiazol-2-yl)-benzene-amide-PEG4-ester-2,3,5,6-F-Ph 3094598-90-7
    Di(5-(methylsulfonyl)-1,3,4-oxadiazol-2-yl)-benzene-amide-PEG4-ester-2,3,5,6-F-Ph (Compound L-1026) is a linker that connects Androgen Receptor (AR) RNAi agent to targeting ligands (such as antibodies). The conjugation can inhibit AR gene expression and reduce AR activity. Di(5-(methylsulfonyl)-1,3,4-oxadiazol-2-yl)-benzene-amide-PEG4-ester-2,3,5,6-F-Ph can be used for spinal and bulbar muscular atrophy (SBMA) research.
    Di(5-(methylsulfonyl)-1,3,4-oxadiazol-2-yl)-benzene-amide-PEG4-ester-2,3,5,6-F-Ph
  • HY-176866
    Rodin-A 2222756-46-7 98%
    Rodin-A is an orally active, brain-penetrant and selective histone deacetylase (HDAC)-co-repressor of repressor element-1 silencing transcription factor (CoREST) complex inhibitor with an IC50 value of 1.80 μM for the CoREST complex, 0.15 μM for HDAC1, and 0.43 μM for HDAC2. Rodin-A increases the acetylation level of histone H3K9, upregulates the expression of neuron-related genes, thereby promoting the increase in dendritic spine density, the colocalization of synaptic proteins (SV2A and PSD95), and the improvement of hippocampal long-term potentiation (LTP), exerting synaptic protection and repair activity. Rodin-A is promising for research of neurodegenerative diseases related to synaptic dysfunction, especially Alzheimer’s disease.
    Rodin-A
  • HY-176867
    Rodin-B 98%
    Rodin-B is a selective histone deacetylase (HDAC)-co-repressor of repressor element-1 silencing transcription factor (CoREST) complex inhibitor with an IC50 value of 0.50 μM for the CoREST complex, 0.27 μM for HDAC1, and 0.28 μM for HDAC2. Rodin-B increases the acetylation level of histone H3K9, upregulates the expression of neuron-related genes, thereby promoting the increase in dendritic spine density, the colocalization of synaptic proteins (SV2A and PSD95), and the improvement of hippocampal long-term potentiation (LTP), exerting synaptic protection and repair activity. Rodin-B is promising for research of neurodegenerative diseases related to synaptic dysfunction, especially Alzheimer’s disease.
    Rodin-B
  • HY-176868
    Rodin-C 2065162-16-3 98%
    Rodin-C is a selective HDAC inhibitor with IC50s of 0.059, 0.18   and 5.39 μM for HDAC1, HDAC2 and HDAC11, respectively, over HDAC3-10. Rodin-C significantly inhibits the HDAC-CoREST complex with low hematological toxicity. Rodin-C can be used for neurologic disorders such as Alzheimer’s disease research.
    Rodin-C
  • HY-176910
    IHCH-7179 2813335-02-1
    IHCH-7179 is a 5-HT receptor modulator. IHCH-7179 can antagonize 5-HT2A receptor and activate 5-HT1A receptor. IHCH-7179 can be used for the research of neurological disease.
    IHCH-7179
  • HY-176925
    α-Synuclein aggregate binder 2 3056154-68-5
    α-Synuclein aggregate binder 2 (Compound 1) is a specific alpha-synuclein binder with a Ki of 1.6 nM. α-Synuclein aggregate binder 2 has a weak binding affinity for β-amyloid aggregates with a Ki of 295 nM. α-Synuclein aggregate binder 2 can be used as a tracer in Parkinson's disease.
    α-Synuclein aggregate binder 2
  • HY-176929
    BET-IN-29 1776060-36-6
    BET-IN-29 (Compound 1) is a bromodomain and the terminal motif (BET) inhibitor. BET-IN-29 can be used for the study of cancer, inflammation, metabolism, neurological diseases, and infectious diseases.
    BET-IN-29
  • HY-176936
    Tau-aggregation-IN-5 1283397-08-9 98%
    Tau-aggregation-IN-5 is a Tau-aggregation inhibitor (EC50 = 0.31 μM). Tau-aggregation-IN-5 targets P4HB covalently and activates mild ER stress. Tau-aggregation-IN-4 can be used for the study of neurodegenerative disorders such as Alzheimer’s and Pick’s diseases.
    Tau-aggregation-IN-5
  • HY-176973
    DRP1 Allosteric-IN-1 1359386-11-0
    DRP1 Allosteric-IN-1 (Compound 1) is an allosteric inhibitor of DRP1 with an IC50 value for the DRP1:MiD49 protein-protein interaction of 3.6 μM. DRP1 Allosteric-IN-1 can be used to study various diseases related to mitochondrial division disorders.
    DRP1 Allosteric-IN-1
  • HY-176974
    DRP1 Allosteric-IN-2 3056559-91-9
    DRP1 Allosteric-IN-2 (Compound 2a) is an allosteric inhibitor of DRP1. Its IC50 value for the DRP1:MiD49 protein-protein interaction is 4.3 μM. DRP1 Allosteric-IN-2 can be used to study various diseases related to mitochondrial division disorders.
    DRP1 Allosteric-IN-2
  • HY-176975
    DRP1 Allosteric-IN-3 3056559-92-0
    DRP1 Allosteric-IN-3 (Compound 2b) is an allosteric inhibitor of DRP1. Its IC50 value for the DRP1:MiD49 protein-protein interaction is 11 μM. DRP1 Allosteric-IN-3 can be used to study various diseases related to mitochondrial division disorders.
    DRP1 Allosteric-IN-3
  • HY-176993
    2-Et-AZT 1995864-97-5
    2-Et-AZT is a modified Azidothymidine (HY-17413). 2-Et-AZT inhibits caspase-1 activation. 2-Et-AZT reduces choroidal neovascularization (CNV) volume.
    2-Et-AZT
  • HY-177003
    SM (d18:1/15:0) 121999-58-4
    SM (d18:1/15:0) is a sphingomyelinase inhibitor. SM (d18:1/15:0) is promising for research of neurodegenerative diseases (e.g., Alzheimer's) and metabolic syndrome.
    SM (d18:1/15:0)
  • HY-177016
    LRRK2-IN-19 2839667-09-1
    LRRK2-IN-19 is a PROTAC target protein ligand that can be used to synthesize PROTAC JH-XII-03-02 (HY-155150). JH-XII-03-02 is a highly potent and selective LRRK2 PROTAC degrader, which can be used in Parkinson's disease research.
    LRRK2-IN-19
  • HY-177085
    Fumiporexant 2839408-03-4
    Fumiporexant (Compound Example 93) is an orally active, brain-penetrant and selective Orexin receptor 2 (OX2R) antagonist. Fumiporexant regulates the sleep-wake cycle and emotion-related pathways in the central nervous system. Fumiporexant is promising for research of nervous system diseases such as insomnia and major depressive disorder.
    Fumiporexant
Cat. No. Product Name / Synonyms Application Reactivity